Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Accrued Liabilities

v3.24.1.u1
Note 8 - Accrued Liabilities
3 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

8.

Accrued Liabilities

 

Accrued liabilities consisted of the following (in thousands):

 

   

March 31, 2024

   

December 31, 2023

 

Clinical trial costs

  $ 689     $ 258  

Research and development services

    637       632  

Compensation

    317       766  

Professional services fees

    150       98  

Other

    22       23  

Total accrued liabilities

  $ 1,815     $ 1,777